Diffuse Cutaneous Systemic Sclerosis Clinical Trial
Official title:
An Open Label Extension Study of Brentuximab Vedotin Treatment in Active Diffuse Cutaneous Systemic Sclerosis (Diffuse Scleroderma)
The purpose of this study is to assess safety and efficacy of Brentuximab vedotin, a CD30-directed antibody-drug conjugate, in patients with active diffuse cutaneous systemic sclerosis (dcSSc) who relapsed after discontinuation of Brentuximab vedotin.
Systemic sclerosis (SSc, Scleroderma) is a multisystem autoimmune disease characterized by widespread vascular injury and progressive fibrosis of the skin and internal organs. Internal organ involvement results in increased mortality of SSc patients. There is no effective treatment for the majority of patients with early active diffuse scleroderma (diffuse cutaneous systemic sclerosis; dcSSc). It's possible to reverse immune inflammation and reduce the probability of irreversible fibrosis early in the disease course via significant immune modulation. The preliminary results of the Phase II study of Brentuximab vedotin (Protocol BV201708) in SSc demonstrated the short-term safety and benefits of this treatment as many participants already achieved the primary endpoint at 24 weeks. This study is proposed as an extension of the ongoing protocol for up to 48 weeks to make the treatment available for SSc patients who have significantly improved on Brentuximab vedotin, but relapsed after discontinuation of the treatment. Similar to the ongoing Phase II study, the Health Assessment Questionnaire Disability Index (HAQ-DI), patient and physician global scores, inflammatory markers (ESR, CRP), and combined response index in SSc (CRISS) and changes in CD30-stained cells on skin biopsies with IHC will all be exploratory outcomes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02161406 -
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT04137224 -
Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
|
Phase 2 | |
| Not yet recruiting |
NCT04986605 -
Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT02503644 -
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Enrolling by invitation |
NCT05626751 -
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
|
Phase 2 | |
| Withdrawn |
NCT05098145 -
A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Terminated |
NCT04478994 -
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1 | |
| Completed |
NCT03198689 -
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Terminated |
NCT04680975 -
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT00433186 -
Mycophenolate Mofetil in Systemic Sclerosis
|
Phase 1 | |
| Terminated |
NCT03919799 -
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Not yet recruiting |
NCT06152172 -
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
|
Phase 1 | |
| Suspended |
NCT04166552 -
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Not yet recruiting |
NCT06375005 -
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05270668 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
|
Phase 2 | |
| Recruiting |
NCT05168215 -
Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
|
||
| Completed |
NCT04440592 -
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
|
Phase 2 | |
| Withdrawn |
NCT04138485 -
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
|
Phase 2 | |
| Terminated |
NCT03398837 -
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
|
Phase 3 |